198 related articles for article (PubMed ID: 25283374)
1. DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma.
Whorton J; Sureban SM; May R; Qu D; Lightfoot SA; Madhoun M; Johnson M; Tierney WM; Maple JT; Vega KJ; Houchen CW
Dig Dis Sci; 2015 Feb; 60(2):509-13. PubMed ID: 25283374
[TBL] [Abstract][Full Text] [Related]
2. Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett's esophagus and esophageal adenocarcinoma.
Vega KJ; May R; Sureban SM; Lightfoot SA; Qu D; Reed A; Weygant N; Ramanujam R; Souza R; Madhoun M; Whorton J; Anant S; Meltzer SJ; Houchen CW
J Gastroenterol Hepatol; 2012 Apr; 27(4):773-80. PubMed ID: 21916995
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett's Esophagus to Esophageal Adenocarcinoma: a Cross-Sectional Retrospective Study.
Campos VJ; Mazzini GS; Juchem JF; Gurski RR
J Gastrointest Surg; 2020 Jan; 24(1):8-18. PubMed ID: 31745889
[TBL] [Abstract][Full Text] [Related]
4. Genetic profiles of Barrett's esophagus and esophageal adenocarcinoma in Japanese patients.
Tokunaga M; Okimoto K; Akizue N; Ishikawa K; Hirotsu Y; Amemiya K; Ota M; Matsusaka K; Nishimura M; Matsushita K; Ishikawa T; Nagashima A; Shiratori W; Kaneko T; Oura H; Kanayama K; Ohta Y; Taida T; Saito K; Matsumura T; Chiba T; Mochizuki H; Arai M; Kato J; Ikeda JI; Omata M; Kato N
Sci Rep; 2021 Sep; 11(1):17671. PubMed ID: 34480065
[TBL] [Abstract][Full Text] [Related]
5. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
6. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.
Critchley-Thorne RJ; Davison JM; Prichard JW; Reese LM; Zhang Y; Repa K; Li J; Diehl DL; Jhala NC; Ginsberg GG; DeMarshall M; Foxwell T; Jobe BA; Zaidi AH; Duits LC; Bergman JJ; Rustgi A; Falk GW
Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):240-248. PubMed ID: 27729357
[TBL] [Abstract][Full Text] [Related]
7. Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma.
Christman EM; Chandrakesan P; Weygant N; Maple JT; Tierney WM; Vega KJ; Houchen CW
Biomark Res; 2019; 7():5. PubMed ID: 30899515
[TBL] [Abstract][Full Text] [Related]
8. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells.
Qu D; Johnson J; Chandrakesan P; Weygant N; May R; Aiello N; Rhim A; Zhao L; Zheng W; Lightfoot S; Pant S; Irvan J; Postier R; Hocker J; Hanas JS; Ali N; Sureban SM; An G; Schlosser MJ; Stanger B; Houchen CW
PLoS One; 2015; 10(2):e0118933. PubMed ID: 25723399
[TBL] [Abstract][Full Text] [Related]
9. Nanoscale markers of esophageal field carcinogenesis: potential implications for esophageal cancer screening.
Konda VJ; Cherkezyan L; Subramanian H; Wroblewski K; Damania D; Becker V; Gonzalez MH; Koons A; Goldberg M; Ferguson MK; Waxman I; Roy HK; Backman V
Endoscopy; 2013 Dec; 45(12):983-8. PubMed ID: 24019132
[TBL] [Abstract][Full Text] [Related]
10. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
[TBL] [Abstract][Full Text] [Related]
11. Goblet Cell Ratio in Combination with Differentiation and Stem Cell Markers in Barrett Esophagus Allow Distinction of Patients with and without Esophageal Adenocarcinoma.
Schellnegger R; Quante A; Rospleszcz S; Schernhammer M; Höhl B; Tobiasch M; Pastula A; Brandtner A; Abrams JA; Strauch K; Schmid RM; Vieth M; Wang TC; Quante M
Cancer Prev Res (Phila); 2017 Jan; 10(1):55-66. PubMed ID: 27807078
[TBL] [Abstract][Full Text] [Related]
12. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.
Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J
Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927
[TBL] [Abstract][Full Text] [Related]
13. Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma.
Rizk NP; Servais EL; Tang LH; Sima CS; Gerdes H; Fleisher M; Rusch VW; Adusumilli PS
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):482-6. PubMed ID: 22237988
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus.
Shah AK; Hartel G; Brown I; Winterford C; Na R; Cao KL; Spicer BA; Dunstone MA; Phillips WA; Lord RV; Barbour AP; Watson DI; Joshi V; Whiteman DC; Hill MM
Mol Cell Proteomics; 2018 Dec; 17(12):2324-2334. PubMed ID: 30097534
[TBL] [Abstract][Full Text] [Related]
15. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
Ishimura N; Amano Y; Sanchez-Siles AA; Fukuhara H; Takahashi Y; Uno G; Tamagawa Y; Mishima Y; Yuki T; Ishihara S; Kinoshita Y
J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
[TBL] [Abstract][Full Text] [Related]
16. Profiling of circulating microRNAs in patients with Barrett's esophagus and esophageal adenocarcinoma.
Bus P; Kestens C; Ten Kate FJ; Peters W; Drenth JP; Roodhart JM; Siersema PD; van Baal JW
J Gastroenterol; 2016 Jun; 51(6):560-70. PubMed ID: 26585599
[TBL] [Abstract][Full Text] [Related]
17. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
19. Aurora kinase A in Barrett's carcinogenesis.
Rugge M; Fassan M; Zaninotto G; Pizzi M; Giacomelli L; Battaglia G; Rizzetto C; Parente P; Ancona E
Hum Pathol; 2010 Oct; 41(10):1380-6. PubMed ID: 20656315
[TBL] [Abstract][Full Text] [Related]
20. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
